Skip to main content
PharmaTher Holdings Ltd. logo

PharmaTher Holdings Ltd. — Investor Relations & Filings

Ticker · PHRM ISIN · CA71716H1082 LEI · 529900PIPSZ1ZSWF3A21 CSE Manufacturing
Filings indexed 279 across all filing types
Latest filing 2024-08-21 Capital/Financing Update
Country CA Canada
Listing CSE PHRM

About PharmaTher Holdings Ltd.

https://www.pharmather.com/

PharmaTher Holdings Ltd. is a specialty pharmaceutical company dedicated to the research, development, and commercialization of novel therapeutics, primarily focusing on ketamine and psychedelic compounds. The company's strategy involves advancing three core assets: the KETARX™ portfolio of ketamine drugs, which targets neuropsychiatric and pain disorders; the proprietary PharmaPatch™ microneedle patch platform, designed for the transdermal delivery of ketamine, psychedelics, and GLP-1 drugs; and a 49% ownership interest in Sairiyo Therapeutics Inc., which is developing a patented oral formulation of cepharanthine for infectious diseases and cancer. PharmaTher is focused on achieving regulatory approval for its pipeline candidates to address significant global unmet medical needs in mental health, neurological, and pain disorders.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a news release announcing a debt settlement by SBD Capital Corp. It details the issuance of common shares to settle indebtedness, references related party transaction exemptions under MI 61-101, and mentions board approval. There is no financial statement or detailed financial report included, nor is there mention of an attached or forthcoming report. The content focuses on a financing activity involving capital structure changes through debt settlement by share issuance. This fits the definition of a Capital/Financing Update (CAP). The document length is short (3254 characters), but it is not merely an announcement of a report publication or a regulatory filing. Therefore, the best classification is CAP with high confidence.
2024-08-21 English
News release - English.pdf
Regulatory Filings
2024-08-19 English
News release - English.pdf
Regulatory Filings
2024-05-15 English
News release - English.pdf
Regulatory Filings
2024-05-10 English
News release - English.pdf
Regulatory Filings
2024-05-01 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a FORM 52-109FV2 Certification of Interim Filings for a venture issuer, signed by the CEO. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended February 29, 2024. The document is a certification letter and does not contain actual financial statements or substantive financial data. It explicitly states it is a certification and notes the absence of representations related to internal controls. According to the CERTIFICATION RULE, such officer certifications should be classified as Regulatory Filings (RNS), not as the interim report itself. The document length is 3071 characters, which is relatively short and consistent with a certification letter rather than a full interim report.
2024-04-23 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.